MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms

Seminars in Oncology

Volumn 42, Issue 6, 2015, Pages 849-862

  Wu, Pui Kei ^a   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2 FLUORO 4 IODOANILINO) 1,6 DIHYDRO N (2 HYDROXYETHOXY) 1,5 DIMETHYL 6 OXONICOTINAMIDE; 3 (2,3 DIHYDROXYPROPYL) 6 FLUORO 5 (2 FLUORO 4 IODOANILINO) 8 METHYLPYRIDO[2,3 D]PYRIMIDINE 4,7 DIONE; 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; BINIMETINIB; COBIMETINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; REFAMETINIB; SELUMETINIB; TRAMETINIB; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME MECHANISM; HUMAN; INHIBITION KINETICS; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84962305085     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.023     Document Type: Review

References (113)

1. L.B. Ray, and T.W. Sturgill Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro Proc Natl Acad Sci U S A 84 1987 1502 1506
2. L.B. Ray, and T.W. Sturgill Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells J Biol Chem 263 1988 12721 12727
3. T.G. Boulton, G.D. Yancopoulos, J.S. Gregory, and et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control Science 249 1990 64 67
4. Y.D. Shaul, and R. Seger The MEK/ERK cascade: from signaling specificity to diverse functions Biochim Biophys Acta 1773 2007 1213 1226
5. S. Yoon, and R. Seger The extracellular signal-regulated kinase:multiple substrates regulate diverse cellular functions Growth Factors 24 2006 21 44
6. A. von Kriegsheim, D. Baiocchi, M. Birtwistle, and et al. Cell fate decisions are specified by the dynamic ERK interactome Nat Cell Biol 11 2009 1458 1464
7. G. Pearson, F. Robinson, T. Beers Gibson, and et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr Rev 22 2001 153 183
8. I. Wortzel, and R. Seger The ERK cascade: distinct functions within various subcellular organelles Genes Cancer 2 2011 195 209
9. R. Roskoski Jr ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 66 2012 105 143
10. J.A. McCubrey, L.S. Steelman, W.H. Chappell, and et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response Oncotarget 3 2012 954 987
11. A.S. Dhillon, S. Hagan, O. Rath, and W. Kolch MAP kinase signalling pathways in cancer Oncogene 26 2007 3279 3290
12. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
13. M.C. Lawrence, A. Jivan, C. Shao, and et al. The roles of MAPKs in disease Cell Res 18 2008 436 442
14. H. Davies, G.R. Bignell, C. Cox, and et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
15. E. Puxeddu, S. Moretti, R. Elisei, and et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas J Clin Endocrinol Metab 89 2004 2414 2420
16. E. Tiacci, V. Trifonov, G. Schiavoni, and et al. BRAF mutations in hairy-cell leukemia N Engl J Med 364 2011 2305 2315
17. M.S. Brose, P. Volpe, M. Feldman, and et al. BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
18. G. Badalian-Very, J.A. Vergilio, B.A. Degar, and et al. Recurrent BRAF mutations in Langerhans cell histiocytosis Blood 116 2010 1919 1923
19. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
20. M.A. Chapman, M.S. Lawrence, J.J. Keats, and et al. Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
21. G. Singer, R. Oldt 3rd, Y. Cohen, and et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
22. I.A. Prior, P.D. Lewis, and C. Mattos A comprehensive survey of Ras mutations in cancer Cancer Res 72 2012 2457 2467
23. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 2002 934
24. K.E. Mercer, and C.A. Pritchard Raf proteins and cancer: B-Raf is identified as a mutational target Biochim Biophys Acta 1653 2003 25 40
25. N.L. Sieben, P. Macropoulos, G.M. Roemen, and et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours J Pathol 202 2004 336 340
26. S. Cowley, H. Paterson, P. Kemp, and C.J. Marshall Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells Cell 77 1994 841 852
27. S.J. Mansour, W.T. Matten, A.S. Hermann, and et al. Transformation of mammalian cells by constitutively active MAP kinase kinase Science 265 1994 966 970
28. J.F. Ohren, H. Chen, A. Pavlovsky, and et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat Struct Mol Biol 11 2004 1192 1197
29. T.O. Fischmann, C.K. Smith, T.W. Mayhood, and et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors Biochemistry 48 2009 2661 2674
30. N.G. Ahn, R. Seger, R.L. Bratlien, C.D. Diltz, N.K. Tonks, and E.G. Krebs Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase J Biol Chem 266 1991 4220 4227
31. N. Gomez, and P. Cohen Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases Nature 353 1991 170 173
32. S.J. Mansour, J.M. Candia, J.E. Matsuura, M.C. Manning, and N.G. Ahn Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1 Biochemistry 35 1996 15529 15536
33. B. Xu, J.L. Wilsbacher, T. Collisson, and M.H. Cobb The N-terminal ERK-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo J Biol Chem 274 1999 34029 34035
34. M. Fukuda, I. Gotoh, Y. Gotoh, and E. Nishida Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal J Biol Chem 271 1996 20024 20028
35. M. Fukuda, I. Gotoh, M. Adachi, Y. Gotoh, and E. Nishida A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase J Biol Chem 272 1997 32642 32648
36. H. Jaaro, H. Rubinfeld, T. Hanoch, and R. Seger Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation Proc Natl Acad Sci U S A 94 1997 3742 3747
37. H. Cha, E.K. Lee, and P. Shapiro Identification of a C-terminal region that regulates mitogen-activated protein kinase kinase-1 cytoplasmic localization and ERK activation J Biol Chem 276 2001 48494 48501
38. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem Sci 36 2011 65 77
39. R. Roskoski Jr MEK1/2 dual-specificity protein kinases:structure and regulation Biochem Biophys Res Commun 417 2012 5 10
40. A. Dang, J.A. Frost, and M.H. Cobb The MEK1 proline-rich insert is required for efficient activation of the mitogen-activated protein kinases ERK1 and ERK2 in mammalian cells J Biol Chem 273 1998 19909 19913
41. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc Natl Acad Sci U S A 103 2006 17783 17788
42. D.R. Alessi, Y. Saito, D.G. Campbell, and et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1 Embo J 13 1994 1610 1619
43. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat Chem Biol 2 2006 358 364
44. C. Pargellis, L. Tong, L. Churchill, and et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat Struct Biol 9 2002 268 272
45. L.N. Johnson, E.D. Lowe, M.E. Noble, and D.J. Owen The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases FEBS Lett 430 1998 1 11
46. P. Traxler, and P. Furet Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacol Ther 82 1999 195 206
47. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
48. N.S. Gray, L. Wodicka, A.M. Thunnissen, and et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538
49. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, and J.R. Peterson Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat Biotechnol 29 2011 1039 1045
50. M.I. Davis, J.P. Hunt, S. Herrgard, and et al. Comprehensive analysis of kinase inhibitor selectivity Nat Biotechnol 29 2011 1046 1051
51. A.M. Grimaldi, E. Simeone, and P.A. Ascierto The role of MEK inhibitors in the treatment of metastatic melanoma Curr Opin Oncol 26 2014 196 203
52. A.M. Menzies, and G.V. Long Systemic treatment for BRAF-mutant melanoma:where do we go next? Lancet Oncol 15 2014 e371 e381
53. Y. Zhao, and A.A. Adjei The clinical development of MEK inhibitors Nat Rev Clin Oncol 11 2014 385 400
54. D.T. Dudley, L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel A synthetic inhibitor of the mitogen-activated protein kinase cascade Proc Natl Acad Sci U S A 92 1995 7686 7689
55. M.F. Favata, K.Y. Horiuchi, E.J. Manos, and et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase J Biol Chem 273 1998 18623 18632
56. D.R. Alessi, A. Cuenda, P. Cohen, D.T. Dudley, and A.R. Saltiel PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo J Biol Chem 270 1995 27489 27494
57. N.G. Ahn, T.S. Nahreini, N.S. Tolwinski, and K.A. Resing Pharmacologic inhibitors of MKK1 and MKK2 Methods Enzymol 332 2001 417 431
58. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 2000 95 105
59. S. Kamakura, T. Moriguchi, and E. Nishida Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus J Biol Chem 274 1999 26563 26571
60. E.M. Wauson, M.L. Guerra, B. Barylko, J.P. Albanesi, and M.H. Cobb Off-target effects of MEK inhibitors Biochemistry 52 2013 5164 5166
61. D.H. Williams, S.E. Wilkinson, T. Purton, A. Lamont, H. Flotow, and E.J. Murray Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity Biochemistry 37 1998 9579 9585
62. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, and et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 5 1999 810 816
63. A.M. Delaney, J.A. Printen, H. Chen, E.B. Fauman, and D.T. Dudley Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352 Mol Cell Biol 22 2002 7593 7602
64. L.F. Allen, J. Sebolt-Leopold, and M.B. Meyer CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK) Semin Oncol 30 2003 105 116
65. J.S. Sebolt-Leopold, and R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 2004 937 947
66. C.K. Smith, and W.T. Windsor Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry Biochemistry 46 2007 1358 1367
67. S.D. Barrett, A.J. Bridges, D.T. Dudley, and et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Bioorg Med Chem Lett 18 2008 6501 6504
68. D.B. Solit, L.A. Garraway, C.A. Pratilas, and et al. BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
69. P. Lito, A. Saborowski, J. Yue, and et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Cancer Cell 25 2014 697 710
70. T.C. Yeh, V. Marsh, B.A. Bernat, and et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 2007 1576 1583
71. B.R. Davies, A. Logie, J.S. McKay, and et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol Cancer Ther 6 2007 2209 2219
72. H. Huynh, K.C. Soo, P.K. Chow, and E. Tran Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma Mol Cancer Ther 6 2007 138 146
73. N.K. Haass, K. Sproesser, T.K. Nguyen, and et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel Clin Cancer Res 14 2008 230 239
74. J. Farley, W.E. Brady, V. Vathipadiekal, and et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum:an open-label, single-arm, phase 2 study Lancet Oncol 14 2013 134 140
75. T. Bekaii-Saab, M.A. Phelps, X. Li, and et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers J Clin Oncol 29 2011 2357 2363
76. B.B. Friday, C. Yu, G.K. Dy, and et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins Cancer Res 68 2008 6145 6153
77. P.A. Wabnitz, D. Mitchell, and D.A. Wabnitz In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human Pharm Res 21 2004 1670 1679
78. K.D. Rice, N. Aay, N.K. Anand, and et al. Novel Carboxamide-based allosteric mek inhibitors: discovery and optimization efforts toward XL518 (GDC-0973) ACS Med Chem Lett 3 2012 416 421
79. G. Hatzivassiliou, J.R. Haling, H. Chen, and et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers Nature 501 2013 232 236
80. C. Iverson, G. Larson, C. Lai, and et al. RDEA119/BAY 869766:a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer Cancer Res 69 2009 6839 6847
81. A.G. Gilmartin, M.R. Bleam, A. Groy, and et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 17 2011 989 1000
82. J.R. Infante, L.A. Fecher, G.S. Falchook, and et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib:a phase 1 dose-escalation trial Lancet Oncol 13 2012 773 781
83. G.S. Falchook, K.D. Lewis, J.R. Infante, and et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol 13 2012 782 789
84. K.T. Flaherty, J.R. Infante, A. Daud, and et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
85. A.M. Alcala, and K.T. Flaherty BRAF inhibitors for the treatment of metastatic melanoma:clinical trials and mechanisms of resistance Clin Cancer Res 18 2012 33 39
86. J.R. Infante, B.G. Somer, J.O. Park, and et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Eur J Cancer 50 2014 2072 2081
87. A.W. Tolcher, J.C. Bendell, K.P. Papadopoulos, and et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors Ann Oncol 26 2015 58 64
88. A.W. Tolcher, A. Patnaik, K.P. Papadopoulos, and et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma Cancer Chemother Pharmacol 75 2015 183 189
89. Y. Isshiki, Y. Kohchi, H. Iikura, and et al. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent Bioorg Med Chem Lett 21 2011 1795 1801
90. N. Ishii, N. Harada, E.W. Joseph, and et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity Cancer Res 73 2013 4050 4060
91. H. Hamidi, M. Lu, K. Chau, and et al. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition Br J Cancer 111 2014 1788 1801
92. J. Thumar, D. Shahbazian, S.A. Aziz, L.B. Jilaveanu, and H.M. Kluger MEK targeting in N-RAS mutated metastatic melanoma Mol Cancer 13 2014 45
93. P.A. Ascierto, D. Schadendorf, C. Berking, and et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations:a non-randomised, open-label phase 2 study Lancet Oncol 14 2013 249 256
94. K. Kim, S.Y. Kong, M. Fulciniti, and et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo Br J Haematol 149 2010 537 549
95. J. Yoon, K.H. Koo, and K.Y. Choi MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy Cancer Res 71 2011 445 453
96. Q. Dong, D.R. Dougan, X. Gong, and et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer Bioorg Med Chem Lett 21 2011 1315 1319
97. E. von Euw, M. Atefi, N. Attar, and et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines Mol Cancer 11 2012 22
98. E.F. Choo, M. Belvin, J. Chan, and et al. Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor Xenobiotica 40 2010 751 762
99. Y. Narita, K. Okamoto, M.I. Kawada, and et al. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model Mol Cancer Ther 13 2014 823 832
100. M. Goto, J. Chow, K. Muramoto, and et al. E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7 (8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities J Pharmacol Exp Ther 331 2009 485 495
101. S.A. Byron, D.C. Loch, C.L. Wellens, and et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status Mol Cancer 11 2012 75
102. N. Wagle, C. Emery, M.F. Berger, and et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096
103. R.B. Cohen, S. Aamdal, M. Nyakas, and et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies Eur J Cancer 49 2013 1521 1529
104. C.R. Miller, K.E. Oliver, and J.H. Farley MEK1/2 inhibitors in the treatment of gynecologic malignancies Gynecol Oncol 133 2014 128 137
105. R.B. Corcoran, D. Dias-Santagata, K. Bergethon, and J.A. Engelman BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation Sci Signal 3 2010 ra84
106. H. Wang, S. Daouti, W.H. Li, and et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation Cancer Res 71 2011 5535 5545
107. C.M. Emery, K.G. Vijayendran, M.C. Zipser, and et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 106 2009 20411 20416
108. B. Dai, J. Meng, M. Peyton, and et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17 Cancer Res 71 2011 3658 3668
109. G. Hatzivassiliou, B. Liu, C. O'Brien, and et al. ERK inhibition overcomes acquired resistance to MEK inhibitors Mol Cancer Ther 11 2012 1143 1154
110. E.M. Goetz, M. Ghandi, D.J. Treacy, N. Wagle, and L.A. Garraway ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors Cancer Res 74 2014 7079 7089
111. M.K. Dougherty, J. Muller, D.A. Ritt, and et al. Regulation of Raf-1 by direct feedback phosphorylation Mol Cell 17 2005 215 224
112. P. Lito, C.A. Pratilas, E.W. Joseph, and et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Cancer Cell 22 2012 668 682
113. R.B. Corcoran, K.A. Cheng, A.N. Hata, and et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128